| Typicality: | 0.505 |
| Saliency: | 0.218 |
| up to the final stage | 4 | temporal |
| with satisfactory drug compliance | 2 | other |
| subject → remain in → the study | 13 |
| subject → remain on → study | 3 |
| negative | neutral | positive |
| 0.090 | 0.842 | 0.067 |
| Raw frequency | 16 |
| Normalized frequency | 0.218 |
| Modifier score | 1.000 |
| Perplexity | 106.905 |